Physician profile
Rebecca E Johnson
NPI 1083864045
$13,644.52
in general payments reported to CMS, 2019-2025
61 companies · $3,054 in 2025
The $3,054 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,836 · 2022: $2,956 · 2023: $2,323 · 2024: $2,476 · 2025: $3,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,566 · Education: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,566.00 |
| Education | $286.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,400.96 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,333.43 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,122.76 | 2021-2025 | Evenity, Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $1,112.39 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Novo Nordisk INC | $746.59 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $745.93 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $668.16 | 2021-2025 | Xarelto, Invega Sustenna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $624.28 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $602.09 | 2021-2025 | Jardiance, Spiriva Respimat |
| Pfizer INC. | $587.59 | 2021-2025 | |
| Lilly USA, LLC | $363.46 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $338.15 | 2021-2025 | Rexulti, Nuedexta |
| Abbott Laboratories | $298.43 | 2021-2023 | Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $283.09 | 2021-2025 | |
| Astellas Pharma US INC | $281.08 | 2021-2025 | Veozah, Myrbetriq |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $278.06 | 2021-2023 | Verquvo, Gardasil 9, M-M-R II |
| Medtronic, INC. | $263.36 | 2022-2025 | Minimed 780g, Prestige LP Cervical Disc System |
| Exact Sciences Corporation | $206.72 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $187.20 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $158.02 | 2024-2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $143.36 | 2021-2025 | Belbuca, Xtampza |
| Takeda Pharmaceuticals U.S.A., INC. | $140.78 | 2021-2025 | Trintellix |
| Amarin Pharma, INC. | $110.87 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.20 | 2022-2025 | |
| Corcept Therapeutics | $102.82 | 2023-2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $98.19 | 2021-2022 | |
| Boston Scientific Corporation | $91.00 | 2021-2025 | Watchman Flx |
| Vanda Pharmaceuticals INC. | $87.03 | 2022-2025 | Fanapt |
| Dexcom, INC. | $85.45 | 2024-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $65.63 | 2022 | |
| Xeris Pharmaceuticals, INC. | $62.36 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $54.33 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $53.83 | 2022-2025 | Zoryve |
| Avanir Pharmaceuticals, INC. | $52.78 | 2021 | |
| Almatica Pharma LLC | $50.56 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $50.52 | 2025 | Gemtesa |
| Horizon Therapeutics Plc | $48.00 | 2021-2022 | |
| Eisai INC. | $46.66 | 2021-2024 | |
| Gilead Sciences, INC. | $45.88 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $45.56 | 2024 | Nuzyra |
| Grifols USA, LLC | $41.63 | 2023-2025 | Prolastin-C Liquid |
| Viiv Healthcare Company | $39.53 | 2024 | Apretude |
| Antares Pharma, INC. | $39.45 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $39.10 | 2023-2024 | Eliquis |
| Sanofi Pasteur INC. | $38.39 | 2022 | |
| Nevro Corp. | $34.17 | 2024 | Senza |
| Axsome Therapeutics, INC. | $30.70 | 2023-2025 | Auvelity, Symbravo |
| Kyowa Kirin, INC. | $29.57 | 2023 | Crysvita |
| Impel Pharmaceuticals INC. | $21.85 | 2022 | |
| Bardy Diagnostics, INC. | $20.62 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.06 | 2022 | |
| Hologic Sales and Service, LLC | $19.74 | 2023 | Thinprep 2000 Processor, Aptima |
| Edwards Lifesciences Corporation | $17.67 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Neurocrine Biosciences, INC. | $15.60 | 2025 | |
| Radius Health, INC. | $15.55 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.84 | 2024 | Voquezna |
| Corium, LLC | $13.31 | 2023 | Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.14 | 2024 | Rexulti |
| Genzyme Corporation | $12.70 | 2023 | |
| Phadia US INC. | $12.56 | 2021 | |
| Therapeuticsmd, INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.